Listen up, traders. Accept the offer and you may miss out.
From a buy-and-hold perspective, CST is a classic case of an R&D company that has developed a successful product that meets a global need, and has strong IP protection.
It has only recently moved into the commercialisation phase and its unit sales are growing rapidly. Yes, the strong $A is knocking prifits, and will continue to do so. But with zero debt, low unit costs and a high gross profit margin, the product should nevertheless rapidly increase sales, making good and growing profits for several years.
Such companies are notoriously difficult to value and I have no doubt a valuer can be persuaded to justify $3.55. But that price does not reflect the blue sky that is achievable in the next 2 years.
If you stick a profit of say $20m and RRR of say 12% into the equation, you get an intrinsic value well above $3.55.
The directors are not serving shareholder interests by recommending acceptance of the offer.
Listen up, traders. Accept the offer and you may miss out. From...
Add to My Watchlist
What is My Watchlist?
